secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001493152-24-022709
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024
--------------------------------------------------------------------------------

- Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.
- Consulting agreement: €104,000 annual compensation, plus options for 15,000 shares at Nasdaq closing price on July 1, 2024, vesting quarterly over 3 years.
- Schellens brings 25+ years oncology experience, former CMO at Byondis B.V., board member of Dutch Medicines Evaluation Board.
- He will lead clinical trial oversight, regulatory strategy, and serve as primary medical monitor.
- Agreement provides for services 2 days per week, based in Netherlands; term until terminated by either party with 60 days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/0001493152-24-022709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-022709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer